ABBV vs ABT
AbbVie Inc. vs Abbott Laboratories · Updated May 11, 2026
ABBV — 14 winsABT — 7 wins
Price Performance
ABBV +6.69%ABT -37.45%
Performance
| ABBV | ABT | |
|---|---|---|
| 1 Month | -2.64% | -17.70% |
| 3 Months | -9.24% | -25.79% |
| 6 Months | -7.49% | -33.96% |
| YTD | -11.31% | -34.35% |
| 1 Year | +9.19% | -38.60% |
| 3 Year | +37.51% | -26.40% |
| 5 Year | +77.91% | -31.19% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | -11.6% | +27.3% | +11.2% | -4.6% | +19.3% | +28.4% | +19.6% | -0.8% | -6.3% | +55.0% | +8.7% | -10.1% |
| ABT | -33.5% | +10.4% | +3.0% | +0.5% | -21.0% | +29.0% | +25.9% | +25.0% | +23.0% | +46.1% | -10.5% | +0.0% |
Valuation
| ABBV | ABT | |
|---|---|---|
| P/E Ratio | 99.37 | 22.91 |
| Forward P/E | 14.13 | 15.41 |
| PEG Ratio | 6.97 | 2.20 |
| P/S Ratio | 5.77 | 3.33 |
| P/B Ratio | -107.64 | 2.27 |
| EV/EBITDA | 12.66 | 16.43 |
Financials
| ABBV | ABT | |
|---|---|---|
| EPS (TTM) | $2.04 | $3.59 |
| Gross Margin | +83.54% | +56.28% |
| Operating Margin | +31.56% | +16.50% |
| Net Margin | +4.66% | +9.65% |
| ROE | -130.92% | +9.50% |
| ROA | +3.15% | +5.07% |
| Debt/Equity | -21.34 | 0.52 |
Growth
| ABBV | ABT | |
|---|---|---|
| Revenue Growth YoY | +12.43% | +7.78% |
| Revenue Growth QoQ | -9.72% | -2.57% |
| EPS Growth YoY | -45.83% | -18.24% |
| EPS Growth QoQ | -61.76% | -39.22% |
Technical
| ABBV | ABT | |
|---|---|---|
| RSI (14) | 44.48 | 21.71 |
| % From 20-Day SMA | -0.86% | -10.20% |
| % From 50-Day SMA | -4.28% | -18.31% |
| % From 200-Day SMA | -7.21% | -31.16% |
| % From 52-Week High | -17.23% | -40.85% |
| % From 52-Week Low | +14.76% | +0.34% |
Analyst Ratings
ABBV
Buy(18 analysts)
Strong SellHoldStrong Buy
Price Target
$256.69
+27.72% upside
ABT
Buy(28 analysts)
Strong SellHoldStrong Buy
Price Target
$128.71
+52.57% upside
Overview
| ABBV | ABT | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Devices |
| Exchange | NYSE | NYSE |
| Market Cap | $362.56B | $150.22B |
| Shares Outstanding | 1.77B | 1.74B |
| Avg Volume (10D) | 6.59M | 13.78M |
| Dividend Yield | 3.29% | 2.83% |
Frequently Asked Questions
Is ABBV or ABT a better buy right now?
Based on 21 comparable metrics, ABBV leads in 14 categories while ABT leads in 7. ABBV has a consensus analyst rating with 18 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, ABBV or ABT?
Over the past year, ABBV returned +9.19% compared to ABT's -38.60%. In the short term (1 month), ABBV returned -2.64% vs ABT's -17.70%.
Is ABBV or ABT more expensive?
ABBV trades at a P/E of 99.37 compared to ABT's 22.91. On a price-to-sales basis, ABBV trades at 5.77x vs ABT's 3.33x. Forward P/E: ABBV at 14.13 vs ABT at 15.41.
Which stock has higher growth, ABBV or ABT?
ABBV's revenue grew +12.43% year-over-year compared to ABT's +7.78%. EPS growth: ABBV at -45.83% vs ABT at -18.24%.
Do ABBV and ABT pay dividends?
ABBV pays a dividend with a yield of 3.29%. ABT pays a dividend with a yield of 2.83%.
Which stock do analysts prefer, ABBV or ABT?
ABBV has 18 analysts with a target price of $256.69 (+27.72% upside). ABT has 28 analysts with a target of $128.71 (+52.57% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.